

Half-year Report

for the year ending 31 December 2022

Table of contents

| Section | Page number |
|---------------------------------------|-------------|
| ESR's half-year scorecard | 2 |
| Financial statements | 8 |
| Notes to the financial statements | 13 |
| Key management personnel remuneration | 17 |
| Directory | 18 |

Presented to the House of Representatives pursuant to section 18 of the Crown Research Institutes Act 1992.

The Institute of Environmental Science and Research Limited (ESR) is a Crown research institute. It was incorporated in June 1992 and is wholly owned by the New Zealand Government. The two shareholding Ministers appoint a Board of Directors to govern the organisation. ESR has science facilities in Auckland, Wellington (Porirua and Wallaceville) and Christchurch.

© ESR 2023

This work is licensed under a Creative Commons. Attribution-Share Alike 3.0 New Zealand Licence. Published February 2023.

ESR's half-year scorecard

There are 28 performance measures set out in ESR's current Statement of Corporate Intent (2022-2027).

Below is a summary of progress against these performance measures as at 31 December 2022:

| Half-year result | Total |
|-----------------------------------|-------|
| Achieved | 2 |
| On track | 19 |
| In progress/being monitored | 3 |
| Only able to be reported annually | 4 |

| Performance measure | Measure purpose and intention | FY23 Target | Reporting frequency | Half-year progress result | Commentary | | | | |
|--|--|--------------------------|----------------------|---------------------------|---|--|--|--|--|
| | | | | | stablish and embed methods d products for customers. | | | | |
| Investment area: Dem | Investment area: Demonstrating co-design and innovation | | | | | | | | |
| New measure: Number of project proposals that are approved for Innovation Funding by the NZ Police/ ESR Strategic Governance Board | Gives insight into the effectiveness of innovation and commercialisation pipeline development. | 4 projects | Reported annually | On track | Two projects have been approved and funded that aim to reduce drug harm. | | | | |
| New measure: Number of projects where co-designed workshops are undertaken between NZ Police and ESR | Gives insight into how ESR is developing its innovation programme through co-design with stakeholders. | 2 co-design workshops | Reported annually | In progress | A co-designed workshop with the Police Service Design team is in discussion and is anticipated to take place in March 2023. | | | | |
| Investment area: Build | ding an innovation pipeline |) | | | | | | | |
| New measure: Number of research projects awarded KiwiNet Tier 1 Pre- Seed funding by the KiwiNet Investment Committee | KiwiNet Tier 1 funding provides funding for costs (e.g., business case preparation, market validation) related to research that can become commercially viable. | 4 projects | Reported annually | On track | Two Tier 1 project proposals have been submitted and approved. A third project proposal is in development for submission. | | | | |
| New measure: Number of research projects awarded KiwiNet Tier 2 Pre- Seed funding by the KiwiNet Investment Committee | This funding supports research that is ready for commercialisation (private sector). | 2 projects | Reported annually | On track | Two project proposals are being developed to be submitted for assessment in the second half of FY 2022 - 2023. | | | | |
| New measure: Number of Emerging Innovator applications awarded by KiwiNet | KiwiNet's Emerging Innovator Programme provides targeted support to early-stage career scientists who will become the future innovators of New Zealand. The Emerging Innovator Programme provides funding to enable scientists to build industry connections and demonstrate a proof-of- | 2 researchers | Reported annually | On track | We received approval in September 2022 for one ESR forensic scientist to enter the KiwiNet Emerging Innovator intake to receive targeted support for a project focused on reducing drug harm. | | | | |

| Performance measure | Measure purpose and intention | FY23 Target | Reporting frequency | Half-year progress result | Commentary |
|--|---|--|----------------------|---------------------------------|--|
| | principle of a disruptive invention. | | | | |
| Upskill ESR's scientists in achieving impact through innovation | Participation in foundational innovation workshops is essential for upskilling ESR's scientists and fostering collaborative approaches that will strengthen an innovation mindset. | ≥20% of ESR's science staff have participated in science innovation workshops | Reported annually | On track | A second cohort of science innovation workshops is planned for late Q3/early Q4 FY23. |
| Investment area: Shap | ping and developing ESR's | commercialisat | ion approach | | |
| New measure: ESR's commercialisation framework proposal is developed and implemented: Innovation pipeline structure defined Project mapping completed | The ability of ESR to take advantage of commercialisation opportunities is key for financial sustainability. The purpose of this activity measure is to understand what projects could be commercialised into products or services that improve wellbeing and economic outcomes through science and technology. | Innovation pipeline structure defined and project mapping completed | Six monthly | On track | A draft innovation pipeline model is in development. This focuses on upskilling our science workforce, designing project funding and stage-gate mechanisms, and establishing commercialisation expertise to work alongside scientists within projects. |
| programmes and inc | reasing Māori collabora | | | mitment to M | āori: Māori-led research |
| | Vai Māpuna programme | | | | |
| Co-designed projects with iwi increase from the FY22 target of 5 | To increase the number of iwi-led co-designed projects. This is a companion measure to the percentage increase in co-designed research projects with iwi. | ≥8 | Reported annually | On track | Our focus continues to be on delivering co-designed and co-led science requested by lwi. Several rohe-specific projects are continuing with all milestones met. We continue to investigate the development of wider programmes of work that meet the requests driven from lwi and the community. |
| Investment area: Kau | papa Māori or Māori-led res | search projects | or services acro | oss ESR | |
| New measure: Percentage increase from FY2022 baseline in the number of co- designed research projects with iwi | This SSIF platform measure's purpose is to demonstrate growth in ESR's investment in a pipeline of mātauranga Māori research. | ≥ 12% | Reported annually | On track | We have established the FY22 baseline at 20 percent, which we will report against at the end of FY23. |
| Investment area: Stra | tegic Science Investment (| SSIF) funding al | location | | |
| Percentage SSIF funding allocated to projects led by / codesigned with Māori | This SSIF platform measure's purpose is to demonstrate growth in ESR's investment in a pipeline of mātauranga Māori research. | ≥ 12% | Reported annually | Achieved | Approximately 22 percent of SSIF funding is currently allocated to building a pipeline of iwi codesigned research. |

| Performance measure | Measure purpose and intention | FY23 Target | Reporting frequency | Half-year progress result | Commentary |
|---|--|---|----------------------|---------------------------|---|
| | Re-shaping ESR's scier reasing Māori collabora | | | mitment to M | āori: Māori-led research |
| Investment area: SS | SIF research impact | | | | |
| New measure: Percentage SSIF investment in cross- platform multi- disciplinary projects | This measures ESR's ability to take a holistic approach to solve problems by taking integrating innovation approaches through greater collaboration internally and externally. | ≥10% | Reported annually | Achieved | There are seven SSIF projects (ongoing and current FY23 projects) that total approximately 19% of current SSIF funding |
| Strategic Objective: | Re-shaping ESR's scier | nce and demon | strating com | mitment to M | lāori: Māori data sovereignty |
| Investment area: Māo | ri data sovereignty prograr | mme | | | |
| New measure: Develop a Māori data sovereignty treaty in practice framework | This is a key, ongoing workstream that is critical for the ethical use, ownership, access, storage and consent of Māori data for research. | Phase two of the programme is delivered by the end of FY23 | Reported annually | On track | Together with ESR's external Māori Leadership roopu, we have developed a draft Māori data sovereignty framework that is in the process of being reviewed. The final draft of the guiding principles that are under development as par of the pan-CRI approach, is on track to be completed by Q4. |
| Māori | | | l reshaping ES | SR's science | : Investment in Mātauranga |
| New measure: Number of new scientists employed as full-time equivalents to uplift mātauranga Māori capability | This is a measure of the ability to integrate mātauranga Māori capability in our science. It is also a measure of establishing ESR as an employer of choice for Māori. | 5 FTE | Reported annually | Reported annually | This measure will be reported at the end of the financial year. |
| Strategic Objective: Uplifting data scienc | Re-shaping the future o | f science, inve | stment in scie | ence capabil | ities and e-infrastructure: |
| Investment area: Stre | ngthening ESR's data scie | nce and uplifting | capability | | |
| New measure: Develop and implement ESR's data science strategy | This strategy will enable ESR to better understand how data is to be used, shared and made accessible. | Strategy implemented | Reported annually | On track | In addition to strengthening ESR's data management capability and data governance practices, we are developing a governance framework. This includes supporting definition work to underpin the framework. ESR's data science strategy is being developed, focusing on building leadership, accessibility and reach |

| Performance measure | Measure purpose and intention | FY23 Target | Reporting frequency | Half-year progress result | Commentary |
|--|--|--|----------------------|---------------------------------|---|
| Strategic Objective: collaboration | Investment in science of | capabilities and | re-shaping E | SR's science | e: Growing research |
| Investment area: Incre | easing international resear | ch collaboration | | | |
| Number of international proposals submitted and accepted | This is a measure of ESR's science collaboration and raises national and international reputation. | ≥3 | Reported annually | Reported annually | Due to the timing of various international funding rounds, this measure can only be reported annually. |
| Investment area: Ove | rall success rate of externa | al research bids | | | |
| The overall success rate of external research bids | This measures ESR's ability to secure external funding as an indicator of the quality and impact of ESR's research. | ≥15% | Reported annually | Reported annually | Due to the timing of various funding rounds, this measure can only be reported annually. |
| Strategic Objective: In | vestment in science capab | oilities and re-sha | aping ESR's sc | ience: Extend | led research capacity |
| Investment area: Exte | ending ESR's research cap | acity and strengt | thening ties wit | th New Zealan | d universities |
| New measure: Number of science graduates recruited to support research activity, innovation and increase ESR's research paper output | The ability to attract high- quality students to ESR will help further lift the quality of ESR's science and create new opportunities for collaboration and innovation with universities and other science organisations. | 2 PhD students 2 post- doctoral students 1 Summer intern undergraduate 2 graduate students | Reported annually | On track | Most of the positions for this initiative are in the process of being filled. To ensure participation from a larger pool of students, we have advertised for a Master's student to support climate change research at ESR. |
| assess workforce sk Investment area: Ens | ills, development needs uring a workforce capabilit | , and priority a y framework is i | reas for inves | stment | orce capability framework to skills, development needs to |
| | or investment to grow cap | - | | | |
| Develop ESR's Workforce capability framework. | Developing a workforce strategy is vital to identifying the organisation's current and future needs. | Workforce capability framework developed and implemented | Reported annually | In progress | With the rollout of the joint ESR-GNS Workday business platform and the work to implement Phase II relating to talent identification, management and staff retention, this programme of work is still to be scoped and resourced. However, these ongoing workstreams will be key to informing ESR's workforce capability framework. Once those workstreams are completed, we will reassess and rescope requirements. |
| Strategic Objective: Zealand society | Creating a thriving org | anisational cul | ture: ESR em | iployee diver | sity is reflective of New |
| | blish employee diversity b | | | | |
| Establish employee diversity baseline and monitor | This measure will help provide a more relevant picture that ESR is a fair and equitable employer and that any biases are identified and eliminated in the workplace. | Improving against an established baseline | Reported annually | In progress | Work is underway to ensure that Workday (the joint ESR-GNS business enterprise platform) is configured to help us collect more comprehensive data on ethnicity, diversity and disability information. This will help us build a more accurate picture of and insights into ESR's diversity profile. |

| Performance measure | Measure purpose and intention | FY23 Target | Reporting frequency | Half-year progress result | Commentary |
|---|---|--|---------------------------------------|---------------------------------|--|
| Strategic Objective: | Creating a thriving orga | anisational cu | lture: Buildin | g cultural cap | pability and competency |
| Investment area: Build | ding foundational cultural o | capability and c | ompetency | | |
| Percentage of staff who have participated in introduction Te Reo courses | This measures ESR's commitment to growing cultural capability, awareness of, and proficiency in the use of te reo. This measure also serves as an indicator of the effectiveness of the te reo courses. | ≥ 40% | Reported annually | On track | As of 30 November 2022, 34 percent of ESR's staff completed introduction Te Reo courses. |
| New measure: Percentage of ESR's permanent staff who have participated in a minimum of two foundational cultural capability courses | ESR's foundational cultural capability courses are central to ESR's overall cultural capability programme. Measuring staff participation and evaluating feedback will be important for ensuring ESR's cultural capability programme is effective. | ≥ 50% | Six monthly/ Reported annually | On track | As of 30 November 2022, 41 percent of ESR's staff have participated in a minimum of two foundational cultural capability courses. We anticipate that we will achieve this target by 30 June 2022. |
| Strategic Objective: ESR's people | Creating a thriving orga | anisational cu | Iture: Improvi | ing the health | n, safety, and wellness of |
| Investment area: Impr | oving ESR's health and sa | | | 3 | |
| New measure: Continue to evolve ESR's critical risk management programme | The critical risk management programme is a key component of ESR's health, safety and wellbeing work programme. Implementing critical risk control plans is essential for closing gaps and minimising risk to staff. | Implement control plans for ESR's critical HSW risks and top events by the end of FY23 | Six monthly / Reported annually | On track | Several significant work streams are in progress as part of ESR's overarching Health, Safety and Wellbeing Assurance programme. These include ESR's Hazardous Substance Programme and the work that is being done to strengthen ESR's framework for investigating and managing laboratory safety issues. A monitoring dashboard has been developed. Phase 5 to 9 of the critical risk programme is underway. |
| and targeted investm | nent in capabilities and e | -infrastructur | е | | ng integrated decision-making |
| Investment area: Esta making | blishing and implementing | a Programme I | Management Of | fice (PMO) to s | support integrated decision- |
| New measure: PMO is resourced and implemented by the end of FY23 | An effective PMO is essential for ensuring integrated project planning to underpin ESR's science and build good project management practice across the organisation. | PMO implemented | Reported annually | On track | ESR's PMO is now fully resourced. The PMO's objectives and work programme are under development. |

| Performance measure | Measure purpose and intention | FY23 Target | Reporting frequency | Half-year progress result | Commentary |
|---|---|--|---------------------------------------|---------------------------------|--|
| Strategic Objective: resilience and contin | | s Systems an | d Processes: | Improving E | ESR's strategic business |
| Investment area: Stre | ngthening ESR's business | resilience and | continuity matu | urity | |
| ESR's business resilience and continuity maturity are managed or enhanced | To ensure that ESR's business resilience planning is in place to enable effective operation in emergencies. | Resilience is maintained at level 4 | Reported annually | Reported annually | Several workstreams contribute to ESR's business continuity and resilience. Progress will be reported at the end of the financial year. |
| Strategic Objective: IT operating model for | | s Systems an | d Processes: | Technology | roadmap: Developing a future |
| Investment area: Deli | ver initiatives in ESR's Ent | erprise Techno | logy Roadmap | | |
| New measure Investment decisions are recommended based on the ESR- wide technology roadmap –focus areas are cloud- based services and security and public health surveillance | ESR's IT Cloud Roadmap is part of its wider Technology Roadmap. ESR is migrating old/legacy IT systems to cloud-based alternatives. | Strategic investments are implemented and system resilience improved | Reported annually | On track | ESR continues to make progress to migrate systems to the Cloud as funding allows and ESR expresses a Cloud preference for all new technology solutions procured. |
| Investment area: Stre | ngthening ESR's cyber sec | curity maturity | | | |
| ESR's cyber security maturing rating is managed or enhanced | ESR assesses its cyber security maturity rating across five areas: IDENTIFY, PROTECT, DETECT, RESPOND and RECOVER. The average percentage increase (or decrease) across the five criteria is reported as the score. | Improving or maintained | Reported annually | On track | We assess ESR's cyber security maturity rating every quarter. ESR's cyber security maturity continues to improve across all five areas we assess against. |
| Strategic Objective: management | Strengthening Busines | s Systems an | d Processes: | Information | management governance and |
| Investment area: Info | rmation management gove | rnance and ma | turity | | |
| New measure: ESR's information management maturity is managed or enhanced | This measure demonstrates how ESR's information management practices strengthen over time. | Establish baseline | Six monthly / Reported annually | On track | The information management work programme is aimed at supporting and aligning best practice information management across ESR. The work programme is progressing well and an assessment of ESR's information practices will be undertaken by 30 June 2023. |
| Strategic Objective: emissions | Strengthening Busines | s Systems an | d Processes: | Sustainabili | ity and reducing carbon |
| Investment area: Sus | tainable business practices | and participat | ing in the pan-0 | CRI sustainabi | ility initiative |
| New measure: ESR's total corporate emissions of carbon dioxide (CO2) are managed or improved | The purpose of this measure is to track ESR's total Co2e over time. | Establish baseline | Reported annually | On track | Several initiatives are under way to support ESR's goal of reducing carbon emissions. A sustainability policy has been developed and a sustainability strategy and performance measures are being developed. |

Financial statements

For the six months ended 31 December 2022

Key Financial Performance Measures

| | 6 months ended 31 December 2022 Actual | Year ended 30 June 2023 Plan | Year ended 30 June 2022 Actual | Year ended 30 June 2021 Actual |
|---|--|------------------------------------|--------------------------------------|--------------------------------------|
| Revenue | \$60m | \$124m | \$111m | \$97m |
| Operating margin Earnings before interest, tax, depreciation and amortisation (EBITDA) as a percentage of revenue | 4.3% | 8.0% | 6.8% | 9.5% |
| Return on equity Net profit after taxation as a percentage of equity | (1.0%) | 3.5% | 0.8% | 2.0% |
| Return on assets Earnings before interest and tax as a percentage of total assets | (1.7%) | (0.5%) | 0.5% | 1.7% |
| Acid test ratio Current assets excluding prepayments and inventory to current liabilities excluding deferred revenue | 3.1 | 2.3 | 2.3 | 2.8 |
| Equity ratio Equity as a percentage of total assets | 62.4% | 67.0% | 63.1% | 67.6% |
| Gearing Debt (including finance lease liabilities) as a percentage of debt and equity | 5.8% | 5.0% | 6.0% | 5.5% |
| Annualised operating margin per FTE Earnings before interest, tax, depreciation and amortisation, per average full-time equivalent employee for the year | \$9,554 | \$17,808 | \$14,300 | \$19,500 |

Statement of Profit or Loss and Other Comprehensive Income For the six months ended 31 December 2022

| Group | Group unaudited 6 months ended 31 December 2022 \$'000s | Group audited 12 months ended 30 June 2022 \$'000s | Group unaudited 6 months ended 31 December 2021 \$'000s |
|--|---|--|---|
| Operating Personus | | | _ |
| Operating Revenue Operating Revenue 2 | 55,320 | 98,531 | 45,885 |
| Strategic science investment funding | 5,171 | 12,234 | 5,256 |
| - Charles and Control and Cont | 60,491 | 110,765 | 51,141 |
| | · | • | · |
| Operating expenses | | | |
| Scientific materials | 5,339 | 10,153 | 4,521 |
| Subcontracting, commissions and royalties | 7,172 | 11,683 | 4,955 |
| Personnel | 34,156 | 61,688 | 29,271 |
| Depreciation and amortisation | 3,455 | 7,061 | 3,606 |
| Other | 11,211 61,333 | 19,753 110,338 | 10,056 52,409 |
| | 61,333 | 110,330 | 52,409 |
| Operating profit / (loss) | (842) | 427 | (1,268) |
| Interest income | 506 | 516 | 214 |
| Interest expense 3 | (75) | (138) | (60) |
| The rest expense | 431 | 378 | 154 |
| | | | |
| Profit / (loss) before income tax expense | (411) | 805 | (1,114) |
| Income tax (benefit) / expense 3 | (118) | 310 | (271) |
| Profit / (loss) for the period attributable to the | | | |
| Shareholder of the parent | (293) | 495 | (843) |
| Other comprehensive income | - | - | - |
| Total profit or loss and other comprehensive income for the period attributable to the shareholder of the parent | (293) | 495 | (843) |

The accompanying notes form an integral part of these financial statements.

Statement of Changes in Equity For the six months ended 31 December 2022

| Group | Share capital \$'000s | Retained earnings \$'000s | Total \$'000s |
|--------------------------------|-----------------------|------------------------------|------------------|
| | | | |
| | | | |
| | | | |
| Balance at 1 July 2021 | 8,494 | 51,633 | 60,127 |
| Profit / (loss) for the period | - | (843) | (843) |
| Other comprehensive income | - | - | |
| Total comprehensive income | - | (843) | (843) |
| Transactions with owners: | | | |
| Dividend | - | - | - |
| Balance at 31 December 2021 | 8,494 | 50,790 | 59,284 |
| Balance at 1 July 2022 | 8,494 | 52,128 | 60,622 |
| Profit / (loss) for the period | - | (293) | (293) |
| Other comprehensive income | - | | |
| Total comprehensive income | - | (293) | (293) |
| Transactions with owners: | | | |
| Dividend | - | - | - |
| Balance at 31 December 2022 | 8,494 | 51,835 | 60,329 |

The accompanying notes form an integral part of these financial statements.

Statement of Financial Position As at 31 December 2022

| | Group unaudited 6 months ended 31 December 2022 | Group audited 12 months ended 30 June 2022 | Group unaudited 6 months ended 31 December 2021 |
|--|--|---|--|
| | \$'000s | \$'000s | \$'000s |
| Non-current assets | | | |
| Property, plant and equipment | 30,779 | 29,382 | 26,132 |
| Intangible assets | 4,811 | 4,979 | 5,472 |
| Right-of-use-assets | 3,643 | 3,844 | 4,006 |
| Investment cash | 500 | 8,000 | 1,000 |
| Other investments | 30 | 30 | 30 |
| Deferred taxation | 1,743 | 1,743 | 180 |
| | 41,506 | 47,978 | 36,820 |
| Current assets | | | _ |
| Cash and cash equivalents | 8,982 | 2,037 | 3,361 |
| Investment cash | 28,500 | 31,023 | 32,523 |
| Trade and other receivables | 12,900 | 9,442 | 11,825 |
| Contract assets | 2,938 | 4,616 | 2,648 |
| Income tax receivable | 667 | - | 1,021 |
| Inventories – scientific materials and consumables | 1,035 | 1,035 | 953 |
| Derivative financial instruments | 125 | - | |
| | 55,147 | 48,153 | 52,331 |
| Current liabilities | | | |
| Trade and other payables | 12,259 | 14,233 | 11,144 |
| Contract liabilities | 12,322 | 8,892 | 7,531 |
| Employee benefits | 6,118 | 5,674 | 4,909 |
| Lease liabilities | 350 | 344 | 335 |
| Income tax payable | - | 802 | - |
| Derivative financial instruments | - 04.040 | 15 | 11 |
| N. C. | 31,049 | 29,960 | 23,930 |
| Net current assets | 24,098 | 18,193 | 28,401 |
| Non-current liabilities | | | |
| Employee benefits | 1,913 | 2,010 | 2,260 |
| Lease liabilities | 3,362 | 3,539 | 3,677 |
| LCasc Habilities | 5,275 | 5,549 | 5,937 |
| | 5,275 | 5,543 | 5,551 |
| Net assets | 60,329 | 60,622 | 59,284 |
| | | | |
| Equity | | | |
| Share capital | 8,494 | 8,494 | 8,494 |
| Retained earnings | 51,835 | 52,128 | 50,790 |
| Total equity | 60,329 | 60,622 | 59,284 |

The accompanying notes form an integral part of these financial statements

Statement of Cash Flows For the six months ended 31 December 2022

| | Group unaudited | Group audited | Group unaudited |
|---|--------------------|------------------|----------------------|
| | 6 months | 12 months | 6 months |
| | ended | ended | ended |
| | 31 December | 30 June | 31 December |
| | 2022 | 2022 | 2021 |
| Note | \$'000s | \$'000s | \$'000s |
| 0.1.5 | | | |
| Cash flows from / (used in) operating activities | | | |
| Cash was provided from: Customers | C4 CC0 | 440 744 | E0 E00 |
| Interest received | 64,660 265 | 110,741 502 | 50,522 |
| interest received | | 111,243 | 232 50,754 |
| Cash was applied to: | 64,925 | 111,243 | 50,754 |
| Suppliers and employees | (61,488) | (99,893) | (49,389) |
| Income tax paid | (1,351) | (1,819) | (1,498) |
| income tax paid | (62,839) | (101,712) | (50,887) |
| Net cash (outflow) / inflow from operating activities 4 | 2,086 | 9,531 | (133) |
| Net cash (outnow) / himow from operating activities 4 | 2,000 | 9,001 | (133) |
| Cash flows from / (used in) investing activities | | | |
| Cash was provided from: | | | |
| Term deposit maturities | 15,773 | 36.049 | 18,549 |
| | 15,773 | 36,049 | 18,549 |
| Cash was applied to: | -, - | | -, |
| Purchase of property, plant and equipment | (3,009) | (6,641) | (1,940) |
| Purchase of intangible assets | (1,901) | (1,066) | (491) |
| Investment in term deposits | (5,750) | (37,523) | (14,523) |
| • | (10,660) | (45,230) | (16,954) |
| Net cash inflow / (outflow) from investing activities | 5,113 | (9,181) | 1,595 |
| | | | |
| Cash flows from / (used in) financing activities | | | |
| Cash was applied to: | | | |
| Repayment of lease liabilities | (254) | (495) | (283) |
| Net cash outflow from financing activities | (254) | (495) | (283) |
| | | | |
| Net increase / (decrease) in cash held | 6,945 | (145) | 1,179 |
| Cash and cash equivalents at the beginning of the | | | |
| period | 2,037 | 2,182 | 2,182 |
| Cash and each equivalents at the end of the period | 9 002 | 2 027 | 2 264 |
| Cash and cash equivalents at the end of the period | 8,982 | 2,037 | 3,361 |

The accompanying notes form an integral part of these financial statements

Notes to the financial statements

1. Statement of significant accounting policies

Reporting entity

These financial statements of the Institute of Environmental Science and Research Limited and its subsidiaries ('ESR' and the 'Group) are for the six months ended 31 December 2022.

ESR is a Crown Entity incorporated and based in New Zealand. Its registered office is at 34 Kenepuru Drive, Porirua.

ESR is a Crown research institute that provides specialist scientific services and research, particularly to the public health, food safety, security and justice systems and the environmental sector.

Statement of compliance

The interim financial statements have been prepared in accordance with the requirements of the Crown Entities Act 2004, the Crown Research Institutes Act 1992, the Companies Act 1993 and the Financial Reporting Act 2013.

Basis of preparation of half yearly report

The condensed consolidated interim financial report for the half year reporting period ended 31 December 2022 has been prepared in accordance with Accounting Standard IAS 34 Interim Financial Reporting.

The interim report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2022.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, except for the estimation of income tax.

The financial statements are prepared on the basis of historical cost, except for financial instruments and long service leave.

The financial statements are presented in New Zealand dollars and all values are rounded to the nearest thousand dollars (\$000).

The results for the six months ended 31 December 2022 and comparative period figures presented in the financial statements are unaudited.

Changes in accounting policies

The accounting policies set out in the 2022 Annual Report have been applied consistently to all the periods in these interim financial statements. There have been no changes in accounting policies from those applied in ESR's 2022 Annual Report. Where necessary, comparative figures have been reclassified for consistency with current year disclosures.

2. Revenue

a) Total operating revenue

| a, | Group | Group | Group |
|---------------------------------------|-------------|-----------|-------------|
| | unaudited | audited | unaudited |
| | 6 months | 12 months | 6 months |
| | ended | ended | ended |
| | 31 December | 30 June | 31 December |
| | 2022 | 2022 | 2021 |
| | \$'000s | \$'000s | \$'000s |
| | | | |
| Revenue from contracts with customers | 55,320 | 98,531 | 45,885 |
| Total operating revenue | 55,320 | 98,531 | 45,885 |

b) Revenue from contracts with customers

i) Disaggregated revenue information

| Group – 6 months ended 31 December 2022 | Domestic \$'000s | International \$'000s | Total \$'000s |
|---|---------------------|--------------------------|------------------|
| | | - | |
| Core government contracts | 38,473 | - | 38,473 |
| Research | 3,585 | 2,522 | 6,107 |
| Commercial products and services | 3,446 | 7,294 | 10,740 |
| | 45,504 | 9,816 | 55,320 |

| Group – year ended 30 June 2022 | Domestic | International | Total |
|---|----------|---------------|---------|
| | \$'000s | \$'000s | \$'000s |
| Core government contracts | 71,239 | - 2.946 | 71,239 |
| Research Commercial products and services | 8,668 | 3,846 | 12,514 |
| | 3,915 | 10.863 | 14,778 |
| | 83,822 | 14,709 | 98,531 |

| Group – 6 months ended 31 December 2021 | Domestic \$'000s | International \$'000s | Total \$'000s |
|---|---------------------|--------------------------|------------------|
| Core government contracts | 33,225 | - | 33,225 |
| Research | 3,945 | 1,521 | 5,466 |
| Commercial products and services | 1,939 | 5,255 | 7,194 |
| | 39,109 | 6,776 | 45,885 |

Note that the overall research output of the Group includes activity funded by \$5,171,000 (2021: \$5,256,000) of Strategic Science Investment Funding. This funding is accounted for as a government grant and not included in the table above.

3. Other profit and loss information

a) Interest expense

| | Group unaudited 6 months | Group audited 12 months | Group unaudited 6 months |
|--------------------------|--------------------------------|-------------------------------|--------------------------------|
| | ended 31 December 2022 | ended 30 June 2022 | ended 31 December 2021 |
| | \$'000s | \$'000s | \$'000s |
| Lease liability interest | 75 | 138 | 60 |
| Total interest expense | 75 | 138 | 60 |

b) Income tax

Income tax expense is recognised based on management's estimate of the weighted average effective annual income tax rate expected for the full financial year. The estimated average annual tax rate used for the six months to 31 December 2022 is 29%, compared to 24% for the six months ended 31 December 2021.

4. Reconciliation of profit / (loss) after taxation to cash flows from operating activities

| | Group | Group | Group |
|--|-------------|-----------|-------------|
| | unaudited | audited | unaudited |
| | 6 months | 12 months | 6 months |
| | ended | ended | ended |
| | 31 December | 30 June | 31 December |
| | 2022 | 2022 | 2021 |
| | \$'000s | \$'000s | \$'000s |
| Profit / (loss) for the period after taxation | (293) | 495 | (843) |
| | , | | |
| Non-cash items: | | | |
| Depreciation and amortisation expense | 3,455 | 7,061 | 3,606 |
| Depreciation on right-of-use assets | 201 | 506 | 259 |
| Gain on modification of lease contracts | - | (110) | (21) |
| Increase/(decrease) in provision for expected credit losses | 4 | 4 | (7) |
| Increase in deferred tax asset | - | (1,563) | - |
| Fair value (gain) / loss on derivative financial instruments | (140) | 24 | 11 |
| Other non-cash items | 7 | (5) | |
| | 3,527 | 5,917 | 3,848 |
| Changes in working capital: | | | |
| Increase in trade and other receivables and contract assets | (1,784) | (2,417) | (2,825) |
| Increase in inventories | - | (161) | (79) |
| Increase in trade and other payables and contract liabilities | 1,456 | 5,480 | 1,030 |
| (Decrease) / increase in income tax payable | (1,469) | 54 | (1,769) |
| Increase in employment benefits | 347 | 809 | 294 |
| | (1,450) | 3,765 | (3,349) |
| Items classified as investing and financing activities: | | | |
| Loss on disposal of property, plant and equipment | 8 | 6 | 3 |
| Decrease / (increase) in payables related to property, plant and | 219 | (790) | 148 |
| equipment | | | |
| Finance charge on leases | 75 | 138 | 60 |
| | 302 | (646) | 211 |
| Net cash inflow / (outflow) from operating activities | 2,086 | 9,531 | (133) |

5. Capital commitments

The following amounts have been committed to by ESR but have not been recognised in the financial statements.

| | Group unaudited 6 months ended 31 December 2022 | Group audited 12 months ended 30 June 2022 | Group unaudited 6 months ended 31 December 2021 |
|-------------------------------|--|---|--|
| Property, plant and equipment | \$'000s 3.557 | \$'000s 3,354 | \$'000s 638 |
| | • | , | |
| Intangible assets - software | 148 | 41 | 10 |
| Total capital commitments | 3,705 | 3,395 | 648 |

6. Contingent liabilities

The directors are satisfied that there are no other claims outstanding that would have a material impact on ESR's financial position as at 31 December 2022 (30 June 2022: Nil).

7. Events subsequent to balance date

There were no events subsequent to reporting date that require disclosure in the financial statements.

Key management personnel remuneration

Key Management Personnel Remuneration

Key management personnel are those with responsibility and authority for planning, directing and controlling the activities of the Group. Key management personnel of the Group are considered to be the Directors, Chief Executive and the senior management team.

Chief Executive's remuneration

The remuneration of our Chief Executive is reviewed annually by the Board and is determined by factors such as advice from external remuneration specialists, including job sizing and market relativity exercises. These are also undertaken on a regular basis and drawn on to inform the determination of salary package.

Chief executive remuneration summary 2019 - 2023

| | Financial year | Salary ^a | STI ^b | Percentage STI against maximum | Benefits ^c | Total |
|--------------|-------------------|---------------------|------------------|--------------------------------------|-----------------------|-----------|
| Peter Lennox | HY2023 | \$276,873 | n/a | n/a | \$8,643 | \$285,516 |
| | 2022 | \$504,858 | n/a | n/a | \$15,594 | \$520,452 |
| | 2021 | \$454,372 | n/a | n/a | \$14,048 | \$468,420 |
| Keith McLea | 2021 | \$134,961 | n/a | n/a | \$19 | \$134,980 |
| | 2020 | \$508,210 | n/a | n/a | \$533 | \$508,743 |
| | 2019 | \$394,746 | \$89,200 | 81% | \$599 | \$484,545 |

^a CE remuneration since 2020 has not included a short-term incentive (STI) component.

Key management remuneration

The total combined remuneration of our key management team (excluding the Chief Executive's remuneration) from 2019 – 2023.

| Financial year | Salary & STI ^a | Benefits ^b | Total | |
|----------------|---------------------------|-----------------------|-------------|---|
| HY2023 | \$1,122,489 | \$35,040 | \$1,157,529 | • |
| 2022 | \$2,223,603 | \$68,629 | \$2,292,232 | |
| 2021 | \$2,104,372 | \$57,595 | \$2,161,967 | |
| 2020 | \$1,463,900 | \$42,189 | \$1,506,089 | |
| 2019 | \$1,827,863 | \$55,489 | \$1,883,352 | |
| | | | | |

^a Senior management remuneration since 2020 has not included a short-term incentive (STI) component. STIs are shown for the year to which they relate but were unpaid as at that balance date.

^b STIs are shown for the year to which they relate but were unpaid as at that balance date.

^c Benefits comprise insurance cover and employer KiwiSaver contributions.

Benefits comprise insurance and employer KiwiSaver contributions.

Directory

ESR's science centres are located in Auckland, Wallaceville and Kenepuru (Wellington region) and Christchurch



